Preparation of dendritic cells for cancer immunotherapy

Abstract

Development of new effective method for cancer therapy is one of the most important trends in the modern medicine. Along with surgery, chemotherapy and radiotherapy, induction of an immune response against the tumor cells is a promising approach for therapy of cancer, particularly metastatic, slowly dividing tumors and cancer stem cells. Induction of the antitumor T-cell immune response involves activation of antigen-presenting cells, which can efficiently present the cancer antigens and activate T-lymphocytes. The immune response may be activated by dendritic cells (DC) loaded with tumor antigens, such as tumor-specific proteins, tumor cell lysates, apoptotic or necrotic tumor cells, as well as nucleic acids encoding tumor antigens. Regardless of the selected source of the tumor antigen, preparation of mature DC is a principal step in the development of anticancer vaccines aimed at the induction of the cytotoxic T-cell immune response. Recently, various research groups have proposed several strategies for producing mature DC, differed by the set of agents used. It has been shown that the maturation strategy influences both their phenotype and the ability to induce the immune response. In this review we have analyzed the results of studies on the various strategies of preparation of mature DCs.

Inhibition of cell growth and down-regulation of telomerase activity by amygdalin in human cancer cell lines

“…Along with chemotherapy, radiotherapy and surgery, immunotherapy also holds a promising approach for cancer therapy; however, development of an effective and efficient method is one of the most interesting subject in the modern research area (Nazarkina & Laktionov 2015). Amygdalin, sometimes known as laetrile or vitamin B17, is one of the natural cyanogenic diglucoside existing in the fruits and nuts, such as cherries, apricots kernels, apples and almonds (Holzbecher et al 1984;Santos Pimenta et al 2014).…”

Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma

“…Among 27 immune-inducible genes, the levels of CD244, KIR3DLI, NRP1, PDCD1LG2, and TNFRSF8 were reduced in UCEC samples and the levels of CD27, CD28, CD70, CD80, CD86, HAVCR2, ICOS, IDO1, LAIR1, PDCD1, TIGIT, TNFRSF18, -25, -9, -14, and VTCN1 were increased in UCEC samples. Dendritic cells (DCs) have specific tumour antigens capable of inducing apoptosis in cancer cells, as well as nucleotide genes encoding pathogen-associated molecular patterns to trigger an immune response [ 35 ]. In the complex tumor microenvironment, B cells have diversity, and a variety of B cells regulate the occurrence and development of tumors.…”